Experiences with low-intervention clinical trials—the new category under the European Union Clinical Trials Regulation
Clinical Trials · 2025
DOI: 10.1177/17407745241309293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, 2025. Verfasst von Amos J de Jong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlan…. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Research Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims Low-intervention clinical trials have been established under the European Union Clinical Trials Regulation (EU 536/2014) which aims to simplify the conduct of clinical trials with authorized medicinal products. There is limited experience with conducting low-intervention trials. Therefore, this study aims to report on experiences and perceived (dis)advantages of low-intervention trials.
Methods
We surveyed representatives of all individual clinical trials registered on the public website of the European Union Clinical Trials Information System between 31 January 2022 and 1 December 2023 that evaluated authorized investigational medicinal products and had at least one investigative site in the European Union. These representatives were approached between June 2023 and January 2024.
Results
We received 70 responses (response rate 21%). Of the respondents, 31 represented a trial registered as low-intervention trial, and 39 represented a trial not registered as a low-intervention trial (hereafter “regular trials”). Simplified clinical trial monitoring and an easier regulatory approval process were perceived as the main advantages of low-intervention trials, with respectively 44% and 34% of the respondents indicating this to be an advantage in low-intervention trials. However, the respondents experienced that stringent and unclear regulatory requirements impeded the conduct of low-intervention trials. Respondents involved with regular trials indicated that 39% of the regular trials met the criteria of a low-intervention trial but were not registered as such, among others due to unfamiliarity with this trial category.
Conclusions
We argue that the simplified procedures for low-intervention trials should be more detailed—for example in regulatory guidance—in the future to further simplify the conduct of clinical trials with authorized investigational medicinal products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
- Division Laboratory and Pharmacy, Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
- Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland.
- Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
ORCID-Profile: Amos J de Jong, Mira Gp Zuidgeest
Zitieren
APA
de Jong, A. J., Gardarsdottir, H., Santa-Ana-Tellez, Y., de Boer, A., & Zuidgeest, M. G. (2025). Experiences with low-intervention clinical trials—the new category under the European Union Clinical Trials Regulation. Clinical Trials. https://doi.org/10.1177/17407745241309293
Vancouver
de Jong AJ, Gardarsdottir H, Santa-Ana-Tellez Y, de Boer A, Zuidgeest MG. Experiences with low-intervention clinical trials—the new category under the European Union Clinical Trials Regulation. Clinical Trials. 2025. doi:10.1177/17407745241309293
BibTeX
@article{deJong2025,
author = {de Jong, Amos J and Gardarsdottir, Helga and Santa-Ana-Tellez, Yared and de Boer, Anthonius and Zuidgeest, Mira Gp},
title = {Experiences with low-intervention clinical trials—the new category under the European Union Clinical Trials Regulation},
journal = {Clinical Trials},
year = {2025},
doi = {10.1177/17407745241309293}
}
EUVIMED